- Home
- MGNX vs ALTO Comparison
MGNX vs ALTO Comparison
Compare MGNX & ALTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- ALTO
- Stock Information
- Founded
- MGNX 2000
- ALTO 2003
- Country
- MGNX United States
- ALTO United States
- Employees
- MGNX N/A
- ALTO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- ALTO Major Chemicals
- Sector
- MGNX Health Care
- ALTO Industrials
- Exchange
- MGNX Nasdaq
- ALTO Nasdaq
- Market Cap
- MGNX 99.7M
- ALTO 90.6M
- IPO Year
- MGNX 2013
- ALTO N/A
- Fundamental
- Price
- MGNX $1.53
- ALTO $1.17
- Analyst Decision
- MGNX Hold
- ALTO Strong Buy
- Analyst Count
- MGNX 6
- ALTO 1
- Target Price
- MGNX $3.20
- ALTO $5.50
- AVG Volume (30 Days)
- MGNX 1.0M
- ALTO 147.2K
- Earning Date
- MGNX 11-04-2025
- ALTO 11-05-2025
- Dividend Yield
- MGNX N/A
- ALTO N/A
- EPS Growth
- MGNX N/A
- ALTO N/A
- EPS
- MGNX N/A
- ALTO N/A
- Revenue
- MGNX $165,495,000.00
- ALTO $933,137,000.00
- Revenue This Year
- MGNX N/A
- ALTO N/A
- Revenue Next Year
- MGNX N/A
- ALTO $7.53
- P/E Ratio
- MGNX N/A
- ALTO N/A
- Revenue Growth
- MGNX 303.47
- ALTO N/A
- 52 Week Low
- MGNX $0.99
- ALTO $0.76
- 52 Week High
- MGNX $5.10
- ALTO $2.05
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- ALTO 59.28
- Support Level
- MGNX $1.46
- ALTO $1.01
- Resistance Level
- MGNX $1.77
- ALTO $1.10
- Average True Range (ATR)
- MGNX 0.15
- ALTO 0.05
- MACD
- MGNX -0.04
- ALTO 0.01
- Stochastic Oscillator
- MGNX 9.21
- ALTO 62.50
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.